Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Fruit snack could deliver Gut-Boosting bacteria directly to the intestine

NCT ID NCT07679490

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study investigates whether a fruit snack containing microencapsulated Lactobacillus rhamnosus can survive digestion and establish itself in the gut to improve microbiome diversity and gut-brain axis signaling. Healthy adults aged 25-65 will consume either the probiotic snack or a placebo daily for 28 days in a crossover design. Stool and blood samples will measure changes in bacterial abundance, serotonin, and other markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Microencapsulated Lactobacillus rhamnosus fruit snack
What this could lead to
If the probiotic survives digestion and boosts gut microbiome diversity, it could support digestive health and gut-brain communication.
What could go wrong
This is a small, early-stage crossover study in healthy adults, so results may not apply to people with health conditions. The probiotic may not survive the gut or show measurable effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

25 people

The number who actually took part.

Started

Jan 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent prior to any study-related procedure Age 25-65 years-old * BMI range 18.5-31.9 kg/m2 * Willing to abstain from regular consumption of probiotic supplements or food products containing probiotic bacteria (including fermented food and beverages) * Willing to abstain from regular consumption of supplements and medications known to alter gastrointestinal function or inflammatory status during the study Exclusion Criteria: * Smoking * Substance abuse * Pregnancy and lactaction * Diagnosis of type 1 and/or type 2 diabetes * Current (or within the last 4 weeks prior to study start) use of probiotic supplementation. * Immobile (defined as the inability to participate in all study-related procedures) * People with intellectual disabilities. * History of complicated gastrointestinal surgery * Diagnosed inflammatory bowel disease (IBD) * Current diagnosis of psychiatric disease/s or syndromes * Current diagnosis of neurodegenerative disease * Systemic use of antibiotics and/or steroid medication in the last 4 months prior to inclusion * Use of any non-steroidal anti-inflammatory drug (NSAID) more than 3 times a week for the last 2 months * Consumption of any NSAID within 7 days of study start * Any condition which could substantially interfere with intestinal barrier function (e.g. gluten sensitivity, lactose intolerance, celiac disease, IBS, IBD) or in any other way with the outcome of the study, as decided by the principle investigator's discretion * Regular smoking, use of snuff, nicotine, cannabidiol narcotics/supplements, or e-cigarette use * Drinking more than 9 standard cups of alcohol per week and/or more than 3 standard cups of alcohol per occasion * Regular use, for more than three times a week for the last 2 months and/or 7 days prior to inclusion, of medications which according to the principal investigator can have an anti-inflammatory effect or affect in any way the intestinal barrier function or have an impact on the study analysis (such as laxatives, anti-diarrheal, anti-cholinergic, etc.) * After being included in the study, starting any medication or treatment that could potentially influence the study participation and/or study analysis. Justification: it is necessary to exclude participation from individuals with smoking or substance abuse as that may compromise the physiological gut response.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colonization, asymptomatic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Asymptomatic Infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical Research Centre, St. Vincent's University Hospital

    Dublin, Dublin 04, D04 T6F4, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.